Announcement: STADA posts robust sales and profit growth during the first half of the year
STADA Arzneimittel AG, a leading healthcare and pharmaceuticals company, has announced impressive growth in the first half of 2025. According to the company's CEO, Peter Goldschmidt, this growth was achieved despite volatile market conditions.
The company's Specialty segment experienced a double-digit increase in revenues, reaching €486 million, a 18% year-over-year growth. This growth was primarily due to the strong performance and penetration of the Uzpruvo (ustekinumab) biosimilar to Stelara, launched from July 2024. The Specialty segment also benefited from the continued growth of in-market biosimilars such as adalimumab and the introduction of specialty oncology generics nilotinib and paclitaxel albumin in several European countries.
The growth in Specialty revenues was not the only positive news for STADA. The Consumer Healthcare segment also saw growth, with revenues increasing by 2% year-over-year to €779 million. This growth was achieved despite a decline in Q1 2025 related to a weak cough & cold season. The remaining Consumer Healthcare portfolio grew in the mid-single-digit range, driven by the strong performance of key brands such as Nizoral and Zoflora.
Outside of Germany, Generics revenues in other countries increased in the mid-single-digit range during the 2025 first half, driven in part by the launch of the anticoagulant rivaroxaban in several countries.
Overall, STADA reported strong revenues and earnings growth in the first half of 2025. Adjusted cc earnings before interest, tax, depreciation, and amortization (EBITDA) improved by 5% to €481 million.
STADA's commitment to sustainability was also highlighted in the Group Sustainability Report. The report detailed ESG initiatives, and STADA was rated among the top 3% in the sub-industry pharmaceuticals by Sustainalytics, and among the top 4% of all companies assessed by EcoVadis.
In addition, STADA expanded its development portfolio with 50 new Business Development & Licensing deals signed in H1. The company also has a robust pipeline for future growth, including preparations for the approval and launch of Specialty biosimilars such as aflibercept, denosumab, golimumab, and tocilizumab.
In a recent employee survey, 83% of participating employees said they are proud to work for STADA, indicating high employee engagement rates. This, combined with strong launches and a diversified portfolio, positions STADA well for continued growth in the future.
